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Summary Background: Acute exacerbations of asthma and chronic obstructive
pulmonary disease (COPD) are associated with increased airflow limitation,
hyperinflation and respiratory muscle fatigue. It is unclear, whether patients are
able to perform adequate inhalations through various inhalation devices with
different orfices during an exacerbation.
The aim of this study was to examine the evolution of inhalation profiles of
patients inhaling through Diskus, Turbuhaler, pressurized metered dose inhaler
(pMDI) and Volumatic and consequently the appropriateness of using the various
devices during an exacerbation.
Measurements: 15 hospitalized patients participated in this randomized compar-
ison of inhalation profiles through the four placebo-devices. For each device,
triplicate inhalation profiles were recorded during day 1–9 of admission and in stable
phase (day 50).
Results: The mean percentage of patients performing optimum inhalation profiles
was 100% for Diskus, 60% for Turbuhaler, 14% for pMDI and 87% for Volumatic over the
interval of day 1–9 and day 50. Patients with an inspiratory muscle strength (MIP) of
less than 6 kPa were generally unable to generate the optimum flow through the
Turbuhaler (460 l/min).
Conclusion: The Diskus and Volumatic can be used effectively in the acute phase of
an exacerbation of asthma or COPD. The Turbuhaler could be optimally used after
the fifth day of convalescence. The pMDI is rather unsuitable during an exacerbation.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
An acute exacerbation of obstructive lung disease
(e.g. asthma and chronic obstructive pulmonary
disease (COPD)) can be elicited by various
agents, and is associated with considerable symp-
tomatic burden and pathophysiological changes
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and, depending on its severity, a common reason
for hospital admission.1–3
Inhalation therapy with bronchodilators and/or
corticosteroids is the mainstay of the treatment
both in stable disease and during an exacerbation.
During an exacerbation the airway caliber and the
level of hyperinflation changes. Furthermore, the
patients use additional systemic corticosteroids
that may cause myopathy, which in turn, may have
consequences for the patients’ performance using
the various inhalation devices. The use of a
pressurized metered dose inhaler (pMDI) has some
potential drawbacks, such as the required hand–
lung co-ordination. These drawbacks are undesir-
able, especially in the acute situation.
The use of dry powder inhalers (DPI) during an
exacerbation may be hampered by decreased
respiratory muscle strength due to hypoxia, hyper-
capnia, hyperinflation and use of corticosteroids.4
Therefore, it is still unclear whether the DPIs could
be effective in the acute phase of an exacerbation.
Furthermore, the various devices have different
orfices and thus different resistivities (resistance to
airflow). One may question, whether patients will
be able to perform adequate inhalations through
high-resistivity devices during an exacerbation.
Should devices be changed during an exacerbation?
The aim of this study was to measure the evolution
of the inhalation profiles using placebo Diskus,
Turbuhaler, pMDI and pMDI plus Volumatic (pMDI V)
in order to evaluate whether one or more devices
are less suitable to be used during an exacerbation.
Asthma and COPD patients performed the inhala-
tion profiles during the acute phase of an exacer-
bation (the day after admission), the phase of
convalescence (day 5 of admission) and in stable
phase (6 weeks after discharge). The second aim
was to investigate whether one or more patient
characteristics (age, various lung function vari-
ables, inspiratory muscle strength) could predict
the ability of the patient to use a certain device
during an exacerbation.
Methods
Study population
Fifteen patients with obstructive pulmonary dis-
ease (five asthmatics and 10 COPD patients; 10
male, mean age 61.4 (11.1) years) admitted for an
acute exacerbation5 participated in the study
(Table 1). Ten patients were ex-smoker; three of
them were still smoking. All of them received
bronchodilators by nebulizer, oral or intravenous
steroids and theophylline. Before the exacerbation,
they used pMDI plus spacer (seven patients), DPI
(four patients) and six patients used pMDI alone.
Exclusion criteria were other pulmonary diseases
(e.g. pneumonia, tuberculosis), a history of thor-
acic surgery and inadequacy to understand instruc-
tions. The hospital ethics committee approved the
study and the participants signed a consent form.
Exacerbations of asthma and COPD were defined
according to previously described criteria.5,6
Study design
The study was performed as an open randomized
comparison of the inhalation profiles performed by
hospitalized patients using a placebo Turbuhalers,
Diskuss, pMDI and pMDI Vs.
Patients were given specific additional verbal and
written instructions, according to instructions on
the manufacturers’ leaflet. They inhaled three
times through each placebo device, in an random
order. The first measurement started between 12
and 24 h after admission (day 1). Measurements
were done at day 1, 2, 3, 4, 5, 6, 7, 8 and 9 (not
during the weekends). Measurements were also
made in a clinically stable condition 6 weeks after
discharge from the hospital (day 50). Each mea-
surement was performed at the same time of the
day, within 3 h after maximal bronchodilation.
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Table 1 Patient characteristics.
Variable Day 1
(exacerbation)
N ¼ 15
Day 50 (stable)
N ¼ 13
FEV1%pr 48.2 (24.7) 59.7 (31.9)
n
FEV1(l) 1.4 (0.8) 1.8 (1.0)
n
FEV1/VC (%) 44.9 (17.2) 48.6 (21.5)
IC (l) 2.0 (0.8) 2.7 (0.8)n
MEF50 (l/s) 0.9 (0.7) 1.6 (1.5)
n
FIV1 (l) 2.2 (1.1) 3.0 (1.0)
n
PIF (l/s) 3.3 (1.7) 4.7 (2.0)n
pH 7.42 (0.004) Not tested
pO2 (kPa) 8.3 (0.97) Not tested
pCO2 (kPa) 5.7 (1.3) Not tested
MIP%pr 62.1 (31.8) 95.7 (32.2)n
MEP%pr 53.1 (22.2) 75.5 (25.0)n
Rrs6 (cmH2O l/s) 4.3 (1.0) 4.0 (1.5)
FEV1%pr: forced expiratory volume in 1 s as percentage of
predicted; FEV1: forced expiratory volume in 1 s; PIF:
peak inspiratory flow; FIV1: forced inspiratory volume in
1 s; FEV1/VC: FEV1/vital capacity; IC: inspiratory capa-
city; MIP%pr and MEP%pr: maximal in- and expiratory
mouth pressure as percentage of predicted; Rrs6: airway
resistance at 6Hz; Data given are mean (SD).
nPo0:05 as compared to day 1.
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Measurements
A flow-volume curve was taken with an integrating
pneumotachograph (Spiro Analyzer SensorMedics,
Bilthoven, The Netherlands). Maximal in- and
expiratory mouth pressure (MIP and MEP) were
measured as described by Wilson et al.7 with a
micro-mouth pressure meter (Micro Medical Ltd.,
UK). Airway resistance (Rrs) was measured with
Forced Oscillation Technique (Random Noise Oscil-
lator, SensorMedics, Bilthoven, The Netherlands).
Inhalation profile
The inhalation profiles of the DPIs were recorded by
a pressure transducer (GlaxoSmithKline R&D De-
partment, Ware, UK), measuring pressures in the
mouthpiece, during inhalation through Diskus and
Turbuhaler. The inhalation profiles were stored into
the inhalation profile recorder.8
The variables of the DPI-inhalation profile re-
corder are peak inspiratory flow (PIF) (l/min);
inhaled volume (Vi) (l) and inhalation time (Ti) (s).
The inhalation profiles of the pMDI and pMDI V
were recorded with a pMDI placed in a pressure-
measuring manifold. The variables of this recorder
are PIF (l/min); Vi (l); Ti (s) and actuation time
(time between the start of the inhalation and the
activation of the canister) (Ta) (s). The variables of
the Volumatic inhalation profiles are actuation time
(Ta)(s) and number of inhalations during the
recorded time.
Optimum use
Previous in vitro studies showed that Diskus operates
effectively at PIF diskus430 l/min.
9,10 Optimum Dis-
kus-use was defined as inhalations with
PIF diskus430 l/min. The Turbuhaler produces a ther-
apeutic dose at PIF430 l/min. However, for the
Turbuhaler, a maximum fine particle mass and
consistent dose delivery has been described at
PIF460 l/min.8,11,12 So, for this study, a PIF turbuhaler
430 l/min is considered ‘minimal’ and PIF turbuhaler
460 l/min as being ‘optimal’.
For the use of a pMDI, an actuation at the start of
a slow inhalation is essential.13 The recommended
flow for the pMDI is between 25 and 90 l/min.14 So,
the optimum pMDI-use was defined as 0:0pTap
0:2 s and 25oPIF pMDIo90 l/min.
We defined optimum Volumatic-use when a
separate puff was inhaled in four tidal breaths
within 20 s, starting between 4 and 0.5 s after
actuation.15,16,17
Statistical analysis
SPSS for Windows version 9.0 and the SAS system
for Windows version 6.12 were used for the
statistical analysis.
Patient characteristics of days 1, 5 and 50 were
compared using the Wilcoxon-matched paired
signed rank test.
The incidences of optimum inhaler use were
calculated. For this analysis the last observation
carried forward method was used to input occa-
sional missing data.
For the evaluation of the various variables,
repeated measurements analysis of variance using
SAS PROC MIXED was used. This statistical program
was also used to evaluate the relationship between
lung function variables and inhalation profiles,
while taking inter- and intra individual differences
into account using random-coefficients models.
Data are expressed as mean 7 SEM or as otherwise
indicated. A two-sided P-value of 0.05 was con-
sidered the limit of significance.
Results
All patients completed at least six measurements
during admission. Two of the 15 patients did not
complete the measurement 6 weeks after dis-
charge.
Incidences of optimum inhalation profiles
We determined which recorded inhalation profiles
could be considered optimal. The incidences (per-
centages) of optimum profiles are shown in Fig. 1.
Diskus
All Diskus inhalations were optimally performed
with PIF430 l/min.
Turbuhaler
All patients were able to generate the minimal
PIF turbuhaler430 l/min. Forty percent of the inhala-
tions through the Turbuhaler were performed with
sub-optimal PIF turbuhalero60 l/min during the ex-
acerbation (day 1–9). There was no significant
difference of the percentage of optimum Turbuha-
ler inhalations (460 l/min), between the inhala-
tions performed during the exacerbation period
(day 1–9) and inhalations performed in the stable
phase (day 50) (60 vs. 64%). So, six (one asthmatic)
of the 15 patients performed all inhalations during
day 1–9 with PIF turbuhalero60 l/min. Four of them
also inhaled in stable phase with PIF turbuhalero60 l/
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min. The two others had dropped out of the study.
Two patients inhaled only on day 1 with
PIF turbuhalero60 l/min, one asthma patient was
unable to generate the optimum flow, up to day 5.
pMDI
The recommended flow for the pMDI is
25oPIFo90 l/min and the optimum actuation time
is between 0.0 and 0.2 s after the start of the
inhalation. Fig. 1 shows that in 14% of the
inhalations both components were correctly per-
formed. In 56% of the pMDI inhalations, the hand–
lung co-ordination was inadequate and 66% were
performed with a too high flow (mean (SD) PIF pMDI:
107.7 (31.7) l/min).
pMDI plus Volumatic
Eighty-seven percent of the Volumatic inhalations
were optimally performed.
Evolution of inhalation profile variables
Table 2 shows the PIF of Diskus and Turbuhaler
during the course of an exacerbation. The mean PIF
values during exacerbation were compared to the
values on day 50. PIF diskus and PIF turbuhaler on day 1
were significantly lower compared to the PIF values
on day 5 and day 50. No significant differences
were found between the PIF values on day 5 and
day 50 for both Diskus and Turbuhaler.
Effects of lung function variables on PIF
The effects of lung function variables on PIF were
evaluated by the repeated measurement ANOVA
(SAS proc. mixed). MIP and MEF50 were found to be
the most significant predictors for PIF diskus. There
was an average increase of 5.0 (0.8) l/min of
PIF diskus per kPa MIP increase (Po0:001). The
average increase of PIF diskus per unit MEF50 was
7.3 (2.1) (Po0:001). MIP and inspiratory capacity
(IC) were found to be the most significant pre-
dictors for PIF turbuhaler. There was an average
increase of 4.3 (0.6) l/min of PIF turbuhaler per kPa
MIP increase (Po0:001). The average increase of
PIF turbuhaler per liter IC was 8.6 (7.5) l/min
(Po0:001). Data are expressed as mean (SEM).
Fig. 2 shows that patients who generated MIPs
less than 6 kPa were generally unable to perform
the optimum PIF turbuhaler (460 l/min).
Discussion
Four different inhalation devices were studied in
hospitalized asthma and COPD patients during a
severe exacerbation.5 The patient characteristics
showed decreased lung function and respiratory
muscle strength variables during the exacerbation.
The aim of this study was to observe the ability of
the patients to use different inhalers and the
evolution of the inhalation profiles through the
four inhalation devices. Furthermore, patient
characteristics predicting optimal use of the
devices were described.
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Figure 1 Incidences of optimum inhalation character-
istics. Diskus: PIF430 l/min; Turbuhaler; PIF460 l/min;
pMDI: 25oPIFo90 l/min and actuation time (T0)
0:0pT0p0:2 s; Volumatic: 4pT0p0:5 s and four inhala-
tions/20 s. The values under the legend were the means
of optimum inhalation profiles over the whole observa-
tion period. The means of the optimum inhalation
profiles over the study period were for Diskus, Turbuhaler,
pMDI and Volumatic, respectively, 100%, 60%, 14% and
87%.
Table 2 Inhalation profile parameters during the course of an exacerbation.
Day 1 (acute phase) Day 5 (phase of convalescence) Day 50 (stable phase)
PIF diskus (l/min) 86 (6.6) [44–131] 95 (7.9) [49–140]
n 101 (7.6) [51–134]n
PIF turbuhaler (l/min) 59 (4.7) [33–88] 67 (5.0) [34–96]
n 72 (5.2) [39–93]n
Data are expressed as mean (SEM) [range].
nPo0:05 as compared to Day 1.
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Incidence of optimum inhalation profiles
(i) All Diskus inhalations were performed at all
times with more than the minimum recom-
mended flow of 30 l/min.
(ii) Turbuhaler: All inhalations were performed
above the minimum flow (430 l/min). So, all
patients should be able to inhale a therapeutic
dose. However, 40% of the inhalations of the
Turbuhaler during the exacerbation period
(day 1–9) were performed with the sub-
optimum flow (o60 l/min). Nine (of 15)
patients failed to generate this flow on day
1. This could be due to decreased respiratory
muscle function since hyperinflated patients
(IC 2.0 (0.8) l and patients with decreased MIP-
values (MIP%pr 62.1) were included in our
study. Fig. 2 shows that, patients who per-
formed MIP less than 6 kPa, were unable to
generate PIF turbuhaler 460 l/min.
Brown et al.18 measured PIF turbuhaler in 99
acute asthma patients (aged 42 years, range
11–88) within 30min of admission. They found
mean PIF turbuhaler of 60 l/min. This was similar
to our PIF turbuhaler day 1 (59 l/min), although
we measured older patients in the acute stage.
Dewar et al.19 showed in 100 (stable and
acute) COPD patients that all patients were
able to perform PIF turbuhaler of 28 l/min and
83% were able to generate PIF turbuhaler 440 l/
min. These data were also similar to our
results: Fig. 2 shows that approximately 90%
of the Turbuhaler-inhalations were performed
with 440 l/min. It has been shown that
recovery of lung function variables to baseline
was incomplete in 7.1% of COPD-patients at 91
days after the start of an exacerbation.20
Therefore, we have to assume that a small
part of our patients were not in ‘stable
condition’ 6 weeks after discharge. However,
after day 5 of the exacerbation, the percen-
tage of patients being able to generate
optimal flows for the various devices did not
differ from the stable period.
(iii) In 56% of the pMDI inhalations, the hand–lung
co-ordination was inadequate and 66% were
performed with a too high flow. In only 14% of
pMDI-inhalations both, major relevant compo-
nents of pMDI-use, were carried out correctly.
Poor pMDI-inhalation technique is well docu-
mented: the frequency of misuse ranges from
14% to 90%.3,21–23 Fifty-four percent of our
patients were pMDI-naive. Another factor that
could be attributed to the bad performance
was the age of our patients. Our patients were
middle-aged. Some studies showed that el-
derly patients are consistently poor perfor-
mers.24,25
(iv) Volumatic: Eighty-seven percent of the Volu-
matic inhalations were optimally performed.
Our findings were in accordance with several
other studies showing the usefulness of pMDI
plus spacer in the acute exacerbation.26–28
Evolution of inhalation profile variables
We compared the PIFs of Diskus and Turbuhaler.
For Diskus it was shown that the PIF day 1 was
significantly lower compared to the values on day 5
and day 50. However, we do not expect that this is
of clinical relevance, because all patients gener-
ated more than the minimum recommended flow of
30 l/min. We found also a decreased PIF turbuhaler on
day 1. In general, patients generated an insufficient
flow during the acute phase of an exacerbation.
Before prescribing the Turbuhaler, one must check
the actual inspiratory flow through a Turbuhaler
using a PIF-meter, with a device specific resistivity
(e.g. In Check Dial, Clement Clarke Int. Ltd. UK) or
patient’s MIP values should exceed 6 kPa.
Effects of lung function variables on PIF
The highest significant correlations were found
between MIP and MEF50 and PIF diskus. The most
significant predictors of PIF turbuhaler were MIP and
IC. These findings confirmed that the ability of
patients to inhale through a DPI depends on their
inspiratory muscle function. The generated
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Figure 2 Relation PIF turbuhaler and MIP. PIF turbuhaler: PIF
of Turbuhaler; MIP: mouth inspiratory pressure. Every dot
represents one measurement (one MIP measurement and
the mean of the three PIF turbuhaler) per patient/day.
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PIF turbuhaler also depends on the inspiratory capacity
(a dimension of hyperinflation). Strength and endur-
ance of the diaphragm of hyperinflated patients is
impaired, because of its unfavorable position on the
length tension curve. A significant correlation be-
tween MIP and IC was found (r ¼ 0:64; Po0:05).
Inhalation of bronchodilators by a nebulizer is the
standard treatment for acute bronchial obstruction
in Europe. In this study, it has been shown that
Diskus and pMDI V can be used effectively in the
acute setting and during the phase of convales-
cence. It has been recommended that larger than
the standard dose of bronchodilators delivered by a
pMDI or DPI should be used for the treatment of
patients with acute airflow obstruction.27
Although, there is a lack of data on optimum drug
dose by hand-held inhalers, it was suggested that
1000 mg of salbutamol via pMDI plus spacer was
equivalent to 2.5mg salbutamol by nebulizer.29 Our
patients inhaled three times through each device
and no effects of fatigue were found, so five puffs
of 200 mg salbutamol via Diskus or pMDI plus spacer
seem to be feasible.
This study has shown the inability of patients to
use a pMDI correctly in the acute phase. A pMDI
should exclusively be used in combination with a
spacer device, especially in the acute setting.
In conclusion, the Diskus and pMDI plus spacer
can be used effectively in the acute phase of an
exacerbation of asthma and COPD. Forty percent of
the patients were able to inhale an optimal dose
from the Turbuhaler in the acute phase, however,
this device could really be optimally used after day
5. Decreased respiratory muscle function predicts a
sub-optimal use of the Turbuhaler. The pMDI is
rather unsuitable without a spacer, especially
during an exacerbation.
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